Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00892749
Recruitment Status : Completed
First Posted : May 4, 2009
Last Update Posted : May 4, 2015
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc

Brief Summary:
This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 for long-term dosing in chronic kidney disease and hyperphosphatemia patients on hemodialysis.

Condition or disease Intervention/treatment Phase
Chronic Kidney Disease Renal Dialysis Renal Insufficiency Hyperphosphatemia Drug: ASP1585 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 248 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Long-term Study in Patients With Chronic Kidney Disease (CKD) and Hyperphosphatemia on Hemodialysis
Study Start Date : May 2009
Actual Primary Completion Date : September 2010
Actual Study Completion Date : September 2010

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 1. ASP1585 Drug: ASP1585
oral
Other Names:
  • ILY101
  • AMG223




Primary Outcome Measures :
  1. Changes in serum Phosphorus level [ Time Frame: After 48 weeks ]

Secondary Outcome Measures :
  1. Percent of the patients meeting the target range of serum Phosphorus levels [ Time Frame: During the treatment ]
  2. Changes in serum Calcium level [ Time Frame: After 48 weeks ]
  3. Changes in serum Ca x P [ Time Frame: After 48 weeks ]
  4. Changes in intact PTH level [ Time Frame: After 48 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Chronic kidney disease patients on hemodialysis
  • Hyperphosphatemia
  • Written informed consent

Exclusion Criteria:

  • Patients with gastrointestinal surgery or enterectomy
  • Severe cardiac disease patients
  • Patients with severe constipation or diarrhea
  • Patients with a complication of malignant tumors
  • Patients with uncontrolled hypertension
  • Patients treated with parathyroid intervention

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00892749


Locations
Layout table for location information
Japan
Chubu, Japan
Chugoku, Japan
Kansai, Japan
Kantou, Japan
Sponsors and Collaborators
Astellas Pharma Inc
Investigators
Layout table for investigator information
Study Chair: Use Central Contact Astellas Pharma Inc
Additional Information:
Layout table for additonal information
Responsible Party: Astellas Pharma Inc
ClinicalTrials.gov Identifier: NCT00892749    
Other Study ID Numbers: 1585-CL-0004
First Posted: May 4, 2009    Key Record Dates
Last Update Posted: May 4, 2015
Last Verified: April 2015
Keywords provided by Astellas Pharma Inc:
hyperphosphatemia
hemodialysis
CKD
ASP1585
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Renal Insufficiency
Hyperphosphatemia
Urologic Diseases
Phosphorus Metabolism Disorders
Metabolic Diseases